Efficacy of Carfilzomib, Lenalidomide, and Dexamethasone for Extramedullary Intracranial Localization of Multiple Myeloma
EMD of myeloma usually occurs several years after diagnosis and is associated with a very poor OS of <6 months due to the fact that there are no efficient treatment options. In rrMM with EMDs, the most effective treatment is a lymphoma-like polychemotherapy regimen such as PACE, Dexa-BEAM, and Hy...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2018/2312430 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560252004859904 |
|---|---|
| author | Giuseppe Mele Domenico Pastore |
| author_facet | Giuseppe Mele Domenico Pastore |
| author_sort | Giuseppe Mele |
| collection | DOAJ |
| description | EMD of myeloma usually occurs several years after diagnosis and is associated with a very poor OS of <6 months due to the fact that there are no efficient treatment options. In rrMM with EMDs, the most effective treatment is a lymphoma-like polychemotherapy regimen such as PACE, Dexa-BEAM, and HyperCVAD followed by ASCT or allogeneic SCT. RT of soft-tissue plasmacytoma is the further treatment choice and results in a high rate of local control and a prolonged disease-free survival. We report the case of a 41-year-old man affected by ultra-high-risk symptomatic IgAλ MM with extramedullary intracranial soft-tissue relapsed after VTD-PACE followed by ASCT. The salvage program with KRd regimen determines a second biochemical and haematological remission and a gradual reduction in size of the extramedullary intracranial soft-tissue even in the absence of local aggressive radiotherapy, suggesting that carfilzomib and lenalidomide together could be effective also in this critical situation. |
| format | Article |
| id | doaj-art-79feb0316640454c853e6a42b2252c6d |
| institution | Kabale University |
| issn | 2090-6560 2090-6579 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-79feb0316640454c853e6a42b2252c6d2025-02-03T01:28:04ZengWileyCase Reports in Hematology2090-65602090-65792018-01-01201810.1155/2018/23124302312430Efficacy of Carfilzomib, Lenalidomide, and Dexamethasone for Extramedullary Intracranial Localization of Multiple MyelomaGiuseppe Mele0Domenico Pastore1Department of Haematology and BMT Unit, Antonio Perrino Hospital, Brindisi, ItalyDepartment of Haematology and BMT Unit, Antonio Perrino Hospital, Brindisi, ItalyEMD of myeloma usually occurs several years after diagnosis and is associated with a very poor OS of <6 months due to the fact that there are no efficient treatment options. In rrMM with EMDs, the most effective treatment is a lymphoma-like polychemotherapy regimen such as PACE, Dexa-BEAM, and HyperCVAD followed by ASCT or allogeneic SCT. RT of soft-tissue plasmacytoma is the further treatment choice and results in a high rate of local control and a prolonged disease-free survival. We report the case of a 41-year-old man affected by ultra-high-risk symptomatic IgAλ MM with extramedullary intracranial soft-tissue relapsed after VTD-PACE followed by ASCT. The salvage program with KRd regimen determines a second biochemical and haematological remission and a gradual reduction in size of the extramedullary intracranial soft-tissue even in the absence of local aggressive radiotherapy, suggesting that carfilzomib and lenalidomide together could be effective also in this critical situation.http://dx.doi.org/10.1155/2018/2312430 |
| spellingShingle | Giuseppe Mele Domenico Pastore Efficacy of Carfilzomib, Lenalidomide, and Dexamethasone for Extramedullary Intracranial Localization of Multiple Myeloma Case Reports in Hematology |
| title | Efficacy of Carfilzomib, Lenalidomide, and Dexamethasone for Extramedullary Intracranial Localization of Multiple Myeloma |
| title_full | Efficacy of Carfilzomib, Lenalidomide, and Dexamethasone for Extramedullary Intracranial Localization of Multiple Myeloma |
| title_fullStr | Efficacy of Carfilzomib, Lenalidomide, and Dexamethasone for Extramedullary Intracranial Localization of Multiple Myeloma |
| title_full_unstemmed | Efficacy of Carfilzomib, Lenalidomide, and Dexamethasone for Extramedullary Intracranial Localization of Multiple Myeloma |
| title_short | Efficacy of Carfilzomib, Lenalidomide, and Dexamethasone for Extramedullary Intracranial Localization of Multiple Myeloma |
| title_sort | efficacy of carfilzomib lenalidomide and dexamethasone for extramedullary intracranial localization of multiple myeloma |
| url | http://dx.doi.org/10.1155/2018/2312430 |
| work_keys_str_mv | AT giuseppemele efficacyofcarfilzomiblenalidomideanddexamethasoneforextramedullaryintracraniallocalizationofmultiplemyeloma AT domenicopastore efficacyofcarfilzomiblenalidomideanddexamethasoneforextramedullaryintracraniallocalizationofmultiplemyeloma |